Skip to main content
. 2019 Jul 1;121(3):199–210. doi: 10.1038/s41416-019-0480-z

Fig. 1.

Fig. 1

Biosimilar development: an overview of the development pathway and the different trastuzumab biosimilar(s) (candidates) approved or in clinical development. a New medicine versus biosimilar medicine development. Adapted from McCamish (2011) Mabs.93 b Key trastuzumab biosimilar candidates approved or in clinical development (status December 2018). EC: European Commission, EMA: European Medicines Agency, MAA: marketing authorisation application